Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial
Bevacizumab is frequently used in the treatment of recurrent WHO grade II and III glioma, but without supporting evidence from randomised trials. Ther…
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
August 13, 2018
|
| In: |
The lancet. Oncology
Year: 2018, Volume: 19, Issue: 9, Pages: 1170-1179 |
| ISSN: | 1474-5488 |
| DOI: | 10.1016/S1470-2045(18)30362-0 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/S1470-2045(18)30362-0 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1470204518303620 
|
| Author Notes: | Martin Bent, Marion Smits, Jaap Reijneveld, Pim French, Paul Clement, Filip Vos, Antje Wick, Paul Mulholland, Martin Taphoorn, Joanne Lewis, Michael Weller, Olivier Chinot, Johan Kros, Iris Heer, Tina Verschuere, Corneel Coens, Vassilis Golfinopoulos, Thierry Gorlia, Ahmed Idbaih |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1692186361 | ||
| 003 | DE-627 | ||
| 005 | 20220818011325.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200310s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1470-2045(18)30362-0 |2 doi | |
| 035 | |a (DE-627)1692186361 | ||
| 035 | |a (DE-599)KXP1692186361 | ||
| 035 | |a (OCoLC)1341309960 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Van den Bent, Martin J. |e VerfasserIn |0 (DE-588)1162295198 |0 (DE-627)1025786866 |0 (DE-576)507313755 |4 aut | |
| 245 | 1 | 0 | |a Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC) |b a randomised controlled phase 2 EORTC trial |c Martin Bent, Marion Smits, Jaap Reijneveld, Pim French, Paul Clement, Filip Vos, Antje Wick, Paul Mulholland, Martin Taphoorn, Joanne Lewis, Michael Weller, Olivier Chinot, Johan Kros, Iris Heer, Tina Verschuere, Corneel Coens, Vassilis Golfinopoulos, Thierry Gorlia, Ahmed Idbaih |
| 264 | 1 | |c August 13, 2018 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 10.03.2020 | ||
| 520 | |a Bevacizumab is frequently used in the treatment of recurrent WHO grade II and III glioma, but without supporting evidence from randomised trials. Ther… | ||
| 700 | 1 | |a Smits, Marion |e VerfasserIn |4 aut | |
| 700 | 1 | |a Reijneveld, Jaap |e VerfasserIn |4 aut | |
| 700 | 1 | |a French, Pim |e VerfasserIn |4 aut | |
| 700 | 1 | |a Clement, Paul |e VerfasserIn |4 aut | |
| 700 | 1 | |a Vos, Filip |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wick, Antje |d 1972- |e VerfasserIn |0 (DE-588)122759869 |0 (DE-627)706032101 |0 (DE-576)293409609 |4 aut | |
| 700 | 1 | |a Mulholland, Paul |e VerfasserIn |4 aut | |
| 700 | 1 | |a Taphoorn, Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lewis, Joanne |e VerfasserIn |4 aut | |
| 700 | 1 | |a Weller, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chinot, Olivier |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kros, Johan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Heer, Iris |e VerfasserIn |4 aut | |
| 700 | 1 | |a Verschuere, Tina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Coens, Corneel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Golfinopoulos, Vassilis |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gorlia, Thierry |e VerfasserIn |4 aut | |
| 700 | 1 | |a Idbaih, Ahmed |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The lancet. Oncology |d London : The Lancet Publ. Group, 2000 |g 19(2018), 9, Seite 1170-1179 |h Online-Ressource |w (DE-627)325349770 |w (DE-600)2035574-9 |w (DE-576)100517544 |x 1474-5488 |7 nnas |a Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC) a randomised controlled phase 2 EORTC trial |
| 773 | 1 | 8 | |g volume:19 |g year:2018 |g number:9 |g pages:1170-1179 |g extent:10 |a Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC) a randomised controlled phase 2 EORTC trial |
| 856 | 4 | 0 | |u https://doi.org/10.1016/S1470-2045(18)30362-0 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S1470204518303620 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200310 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 122759869 |a Wick, Antje |m 122759869:Wick, Antje |d 60000 |d 62700 |e 60000PW122759869 |e 62700PW122759869 |k 0/60000/ |k 1/60000/62700/ |p 8 | ||
| 999 | |a KXP-PPN1692186361 |e 3605714390 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 10.03.2020"],"recId":"1692186361","type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"subtitle":"a randomised controlled phase 2 EORTC trial","title":"Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC)","title_sort":"Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC)"}],"person":[{"family":"Van den Bent","roleDisplay":"VerfasserIn","role":"aut","given":"Martin J.","display":"Van den Bent, Martin J."},{"display":"Smits, Marion","given":"Marion","role":"aut","roleDisplay":"VerfasserIn","family":"Smits"},{"family":"Reijneveld","roleDisplay":"VerfasserIn","role":"aut","given":"Jaap","display":"Reijneveld, Jaap"},{"family":"French","display":"French, Pim","given":"Pim","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Clement","roleDisplay":"VerfasserIn","role":"aut","given":"Paul","display":"Clement, Paul"},{"display":"Vos, Filip","role":"aut","roleDisplay":"VerfasserIn","given":"Filip","family":"Vos"},{"display":"Wick, Antje","role":"aut","roleDisplay":"VerfasserIn","given":"Antje","family":"Wick"},{"family":"Mulholland","roleDisplay":"VerfasserIn","role":"aut","given":"Paul","display":"Mulholland, Paul"},{"display":"Taphoorn, Martin","given":"Martin","roleDisplay":"VerfasserIn","role":"aut","family":"Taphoorn"},{"family":"Lewis","given":"Joanne","role":"aut","roleDisplay":"VerfasserIn","display":"Lewis, Joanne"},{"family":"Weller","display":"Weller, Michael","given":"Michael","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Chinot","display":"Chinot, Olivier","role":"aut","roleDisplay":"VerfasserIn","given":"Olivier"},{"family":"Kros","display":"Kros, Johan","role":"aut","roleDisplay":"VerfasserIn","given":"Johan"},{"family":"Heer","role":"aut","roleDisplay":"VerfasserIn","given":"Iris","display":"Heer, Iris"},{"family":"Verschuere","given":"Tina","role":"aut","roleDisplay":"VerfasserIn","display":"Verschuere, Tina"},{"family":"Coens","display":"Coens, Corneel","role":"aut","roleDisplay":"VerfasserIn","given":"Corneel"},{"family":"Golfinopoulos","display":"Golfinopoulos, Vassilis","roleDisplay":"VerfasserIn","role":"aut","given":"Vassilis"},{"family":"Gorlia","role":"aut","roleDisplay":"VerfasserIn","given":"Thierry","display":"Gorlia, Thierry"},{"given":"Ahmed","roleDisplay":"VerfasserIn","role":"aut","display":"Idbaih, Ahmed","family":"Idbaih"}],"language":["eng"],"name":{"displayForm":["Martin Bent, Marion Smits, Jaap Reijneveld, Pim French, Paul Clement, Filip Vos, Antje Wick, Paul Mulholland, Martin Taphoorn, Joanne Lewis, Michael Weller, Olivier Chinot, Johan Kros, Iris Heer, Tina Verschuere, Corneel Coens, Vassilis Golfinopoulos, Thierry Gorlia, Ahmed Idbaih"]},"id":{"eki":["1692186361"],"doi":["10.1016/S1470-2045(18)30362-0"]},"origin":[{"dateIssuedDisp":"August 13, 2018","dateIssuedKey":"2018"}],"physDesc":[{"extent":"10 S."}],"relHost":[{"id":{"eki":["325349770"],"zdb":["2035574-9"],"issn":["1474-5488"]},"titleAlt":[{"title":"The lancet <London> / Oncology"}],"note":["Gesehen am 22.09.2021"],"recId":"325349770","part":{"pages":"1170-1179","extent":"10","year":"2018","text":"19(2018), 9, Seite 1170-1179","issue":"9","volume":"19"},"pubHistory":["0.2000 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"title":[{"title_sort":"lancet","title":"The lancet","partname":"Oncology"}],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedDisp":"2000-","publisher":"The Lancet Publ. Group","publisherPlace":"London","dateIssuedKey":"2000"}],"disp":"Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC) a randomised controlled phase 2 EORTC trialThe lancet. Oncology","language":["eng"]}]} | ||
| SRT | |a VANDENBENTBEVACIZUMA1320 | ||